| Description | Risedronate Sodium (NE 58095 Sodium) is an aminobisphosphonate derivative of etidronic acid and CALCIUM CHANNEL BLOCKER that inhibits BONE RESORPTION and is used for the treatment of OSTEOPOROSIS. |
| In vitro | Risedronate防止骨膜形成减少,以及内皮质骨侵蚀增加,从而防止皮质骨和骨髓面积百分比的改变.Risedronate增加骨细胞密度和腔隙占用,并防止GC引起的皮质骨松化增加.Risedronate和Vitamin K(2)对骨密度和腔隙占用具有叠加效应,并且对皮质骨松化具有协同作用.1 mg/kg Risedronate在大鼠体内,显着增加骨骼（Vb）和成骨细胞Vob的体积密度并且更显著地降低Vm.Risedronate在大鼠体内,剂量依赖性明显减少使用正畸力后的牙齿移动. |
| In vivo | 1 μM Risedronate减少集落形成,这些集落表现出成骨细胞的特性,比如胶原蛋白聚集,碱性磷酸酶表达,以及钙化作用。1 nM Risedronate和阿仑膦酸钠增加成纤维细胞集落的形成,而具有成骨细胞特性的集落的形成不被影响。Risedronate在大鼠骨髓细胞体外钙化的成纤维细胞集落生成单元的培养物中完全抑制集落形成,而依替膦酸钠具有相对较低的作用。Risedronate在骨髓衍生的巨噬细胞中,明显抑制RANKL诱导的活化T细胞c1的c-Fos和核因子的表达。 |
| Synonyms | NE 58095 Sodium, Risedronic Acid Sodium, 利塞膦酸钠, 利赛膦酸钠 |
| molecular weight | 305.09 |
| Molecular formula | C7H10NNaO7P2 |
| CAS | 115436-72-1 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| Solubility | H2O: 10 mM DMSO: Insoluble |
| References | 1. Still K, et al. Calcif Tissue Int, 2003, 72(2), 143-150. 2. Laghmich A, et al. Eur J Pharmacol, 1998, 348(2-3), 265-270. 3. Cetinkaya BO, et al. J Periodontol, 2008, 79(10), 1950-1961. 4. Ladrière L, et al. Eur J Pharmacol. 1997 Sep 24;335(2-3):227-34. 5. Iwamoto J, et al. Calcif Tissue Int, 2008, 83(2), 121-128. 6. Wu D, Meng B, Cheng Y, et al. The effect of risedronate on orthodontic tooth movement in ovariectomized rats[J]. Archives of Oral Biology. 2019. |
| Citations | 1. Wu D, Meng B, Cheng Y, et al. The effect of risedronate on orthodontic tooth movement in ovariectomized rats. Archives of Oral Biology. 2019 |